The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...

Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Goldman Sachs analyst ...

Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...

Analysts at Citi said that while the clinical hold impacts the targeted commercial launch of the GS-1720/GS-4182 regimen, previously expected around 2029/2030, they believe the setback is minor, as it ...